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Novel proteinNeurotrophic factors are secreted proteins responsible for migration, growth and survival of neurons during
development, and for maintenance and plasticity of adult neurons. Here we present a novel secreted protein
named Cometin which together with Meteorin deﬁnes a new evolutionary conserved protein family. During
early mouse development, Cometin is found exclusively in the ﬂoor plate and from E13.5 also in dorsal root
ganglions and inner ear but apparently not in the adult nervous system. In vitro, Cometin promotes neurite
outgrowth from dorsal root ganglion cells which can be blocked by inhibition of the Janus or MEK kinases.
In this assay, additive effects of Cometin and Meteorin are observed indicating separate receptors. Further-
more, Cometin supports migration of neuroblasts from subventricular zone explants to the same extend as
stromal cell derived factor 1a. Given the neurotrophic properties in vitro, combined with the restricted
inner ear expression during development, we further investigated Cometin in relation to deafness. In neomy-
cin deafened guinea pigs, two weeks intracochlear infusion of recombinant Cometin supports spiral ganglion
neuron survival and function. In contrast to the control group receiving artiﬁcial perilymph, Cometin treated
animals retain normal electrically-evoked brainstem response which is maintained several weeks after treat-
ment cessation. Neuroprotection is also evident from stereological analysis of the spiral ganglion. Altogether,
these studies show that Cometin is a potent new neurotrophic factor with therapeutic potential.n-derived neurotrophic factor;
glion; eABR, Electrically-evoked
C, Fluorescein isothiocyanate;
S/MS, Liquid chromatography
LDI-TOF, Matrix-assisted laser
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During development of the nervous system, cell migration, survival
and differentiation are supported by neurotrophic factors. These secreted
factors are also critical for maintenance and plasticity of the adultnervous system and are furthermore of clinical interest since they may
be therapeutic agents for the treatment of neurodegenerative disorders
and nerve injuries (Levy et al., 2005). Because of their biologically im-
portant and fundamental functions, neurotrophic factors are often
well conserved across species and found in families of closely related
molecules. Historically, the ﬁrst neurotrophic factor discovered was
“nerve growth factor” (NGF) (Levi-Montalcini, 1987) which is the
founding member of the neurotrophin family further consisting of
structurally related, brain-derived neurotrophic factor (BDNF)(Barde
et al., 1982; Leibrock et al., 1989), neurotrophin-3 (NT-3)(Hohn et al.,
1990) and neurotrophin-4/5 (NT 4/5)(Berkemeier et al., 1991; Hallbook
et al., 1991). Several such families of relatedmolecules exist where each
member often has its own preferred receptor and unique characteris-
tics. Recently, Nishino and co-workers discovered Meteorin as a new
neurotrophic factor interestingly not related to any known proteins
(Nishino et al., 2004). Duringmouse development,Meteorin expression
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progenitors and later, foremost to glial cells. In the adult rodent brain,
Meteorin is found in discrete neuronal and glial populations (Jorgensen
et al., 2009; Park et al., 2008). Meteorin is a 30 kDa secretedmonomeric
protein which promotes neurite outgrowth from dorsal root ganglion
cultures. In the central nervous system, Meteorin promotes glial differ-
entiation and seems to have an additional role in cerebral angiogenesis.
The receptor and exact mechanism of action is unknown but lately
Meteorin was shown to use the gp130 co-receptor as an upstream
transducer of Jak-STAT3 signaling (Lee et al., 2010). More recently,
Meteorinwas demonstrated to protect striatal neurons against quinolinic
acid induced excitotoxicity in vivo suggesting important neuroprotective
properties and a therapeutic potential of themolecule in diseases such as
Huntington's disease, stroke, and trauma (Jorgensen et al., 2011). Alto-
gether, Meteorin possesses the properties of a classical neurotrophic
factor.
Following the discovery of Meteorin, a similar transcript was auto-
matically annotated as Meteorin-like in public databases but the hy-
pothetical protein and its function remains undescribed. However,
using a bioinformatics approach, Ramiliason identiﬁed Meteorin-like
as part of a large number of transcripts potentially regulated by the
subfamily of transcription factors including Pax2, Pax5 and Pax8
(Ramialison et al., 2008). With a speciﬁc interest in inner ear develop-
ment, a smaller number of transcripts were next analyzed by whole
mount in situ hybridisation in different developmental stages of me-
daka ﬁsh. Low levels of Meteorin-like mRNAwere detected in the otic
vesicle and the levels were signiﬁcantly increased by Pax2/8 overex-
pression. These data and our interest in Meteorin encouraged us to
study Meteorin-like to better understand its biology and explore its
therapeutic potential.
To accentuate that Meteorin-like is a distinct and unique molecule
we propose the name Cometin (CMTN). In this study we show that
Cometin is a well-conserved secreted neurotrophic protein with tissue
speciﬁc expression during development. In culture, Cometin induces
neurite outgrowth from sensory neurons through the Jak-STAT3 and
MEK-ERK pathways and furthermore promotes subventricular zone
(SVZ) neuroblast migration. In vivo, Cometin has potent neuroprotec-
tive properties illustrated by functional and morphological analysis of
deafened guinea pigs. Hence, together with Meteorin, the two gene
products represent a new family of neurotrophic factors that is structur-
ally unrelated to known protein families.
Materials and methods
Sequence analysis
Homology searches were performed with BLAST (http://www.ncbi.
nlm.nih.gov/blast/Blast/). Alignment of amino acid sequences was done
using CLUSTALW (1.7) (Thompson et al., 1994) in the CloneManager 9
Professional Editionpackage fromSci Ed Software (Cary, NC). Prediction
of signal peptide cleavage sites was done using SignalP (Bendtsen et al.,
2004) and prediction of N-Glycosylation sites was done using
NetNGlyc1.0 (http://www.cbs.dtu.dk/services/NetNGlyc/). Browsers
from USCS and Ensembl were used for genomic analysis.
Cloning and production of recombinant mouse Cometin
The coding sequence of Cometin (Meteorin-like from mouse,
NM_144797) with a C-terminal histidine tag (GSGSGSHHHHHH) was
PCR cloned BamHI/XhoI in pNS1n (Jensen et al., 2002). Correct sequence
was conﬁrmed by DNA sequencing (MWG Biotech AG, Germany). Free-
Style™ 293-F cells (Invitrogen, K9000) were transfected with pNS1n-
mCMTN-HIS DNA using Lipofectamine 2000 (Life Technologies). The
culture was incubated with agitation at 37 °C and 8%CO2 for three days
and separated into cell pellet and supernatant by centrifugation. The su-
pernatant was sterile ﬁltered and recombinant protein puriﬁed withTALONMetal Afﬁnity Resin (Clonetech) followed by PD-10 gel ﬁltration
(GE Healthcare).
SDS-PAGE and Western blotting
Cell lysates and conditioned media were analyzed by Western blot-
ting as previously described (Fjord-Larsen et al., 2005). Brieﬂy, pNS1n-
mCMTN-HIS andmock (pNS1n) transfectionswere done in parallel and
equal amounts of media and lysates loaded respectively to make direct
comparison possible. Detection of Cometin was done using custom
made monoclonal antibody (mAb#645909) at 0.5 μg/ml and HRP-
linked anti-rat Ab (Dako, P0450, 1:2000) as secondary antibody. Alter-
natively gels were stained with PhastGel™ Blue R (GE Healthcare)
according to manufacturer's instructions.
Protein analysis
RP-HPLC, N-terminal sequencing and Mass Spectrometry (MS) was
as previously described (Jorgensen et al., 2009). For peptidemass ﬁnger-
print analysis and liquid chromatography electrospray ionization tan-
dem mass spectrometry (LC-ESI MS/MS) de novo peptide sequencing,
mCMTN-HIS protein band from SDS-PAGE was reduced, alkylated with
iodoacetamide and “in gel” digested with trypsin.
Antibodies
Recombinant mouse Cometin was combined with adjuvant and
used to immunize a male Wistar rat. Lymphocytes were collected
and fused with X63-Ag8.653 mouse myeloma cells using standard
methods (Harlow and Land, 1988). Hybridomas were screened in a
direct ELISA for detection of the immunizing protein, and selected
wells were subcloned three times resulting in 14 monoclonal anti-
bodies. Furthermore, a female sheep was immunized with recombinant
mouse Cometin combinedwith adjuvant and boostedmonthlywith anti-
gen. Blood was collected four months after the initial immunization and
Cometin-speciﬁc antibody puriﬁed on an afﬁnity column made from the
recombinant Cometin. All antibodieswere analyzed by ELISA andwestern
blotting against recombinant Cometin. Furthermore, selected antibodies
were screened on rat brains overexpressing Cometin (Supplementary
Material, S1). The monoclonal rat antibody mAb#645924 (4 μg/ml) and
the polyclonal sheep antibody (0.2 μg/ml)were used for IHC as previously
described (Jorgensen et al., 2009).
In situ hubridization (ISH)
Nucleotide sequences corresponding to bp 292–700 of Cometin
(NM_144797) and 142–587 of Meteorin (NM_133719) were ampli-
ﬁed by PCR with a T7 sequence overhang in the reverse primer.
Digoxigenin labeled antisense riboprobes were generated by in vitro
transcription using the DIG RNA Labeling Kit from Roche according
to the manufacturer. Negative hybridisation controls were similarly
generated by PCR with a T7 overhang in the forward primer. In situ
hybridisation on sections from E9.5, E10.5, E11.5, E13.5 and E14.5
mice embryos was carried out as previously described (Briscoe et
al., 2000). At least three whole embryos were used at each stage.
Dorsal root ganglion (DRG) culture
DRG culture was done as previously described (Jorgensen et al.,
2009). Brieﬂy, dorsal root ganglions from around 15 rat P5 pubs
(male and female) per set-up were dissociated and plated at a cell
density of 1.5×104 cells/cm2. After 1 h, Cometin or Meteorin (R&D
Systems) was added at the indicated concentrations in serum-free
media. In some experiments, JAK inhibitor I (Calbiochem) and the
MEK inhibitor U0126 (Promega) were included at 1 μM. Cells were
incubated at 37 °C and 5% CO2 for 1 day, ﬁxed in 4% PFA and neurons
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ages were taken using an Olympus BX61 microscope, and analysis on
neurite length per cell was subsequently performed using VisioMorph
software (Visiopharm). At least 6–12 images from each of triplicate
wells were analyzed for each experimental condition. Experiments
were independently performed at least three times.
SVZ Explants
In a typical setup, around eight P2–P3 male rat pups were sacri-
ﬁced by decapitation and 250 μm brain sections prepared using a
vibratome. The SVZ was carefully dissected from the lateral wall of
the anterior horn of the lateral ventricle and cut into pieces of 150–
200 μm under a dissecting microscope (MZFLIII, Leica). The SVZ ex-
plants were mixed with Matrigel (Becton Dickinson) and cultured
in four-multiwell plates. After polymerisation, 500 μl Neurobasal me-
dium supplemented with B-27 (Gibco-Invitrogen), N2-factor (Gibco-
Invitrgen) and Penicillin/Streptomycin (Gibco-Invitrogen) were
added to control cultures. The medium was supplemented with dif-
ferent concentrations of recombinant Cometin or SDF1a (Invitrogen)
as indicated. Cultures were maintained in a humidiﬁed 37 °C incubator
at 5% CO2. After 24 h, explants were monitored with a DIC microscope
and the length of migratory chains from each explant was measured
using AxioVision software (Zeiss) and normalized against control. Ex-
periments were independently performed at least three times.
For Doublecortin (DCX) immunocytochemistry, explant cultures
were brieﬂy washed with PBS, ﬁxed with 4% PFA in PBS with 0.05%
Triton-X 100 and incubated with blocking buffer containing 2% horse
serum, 1% BSA, 0.1% gelatin, 0.1% Triton X-100 and 0.05% Tween 20 in
PBS. Next, cultures were incubated with anti-DCX (1:100, Santa Cruz)
as primary antibodies and Cy3-conjugated anti-goat (1:200, Jackson
ImmunoResearch) as secondary antibody. For ﬂuorescein isothiocya-
nate (FITC)-Phalloidin staining, stimulated and control cultures were
rinsed and ﬁxed as described above followed by incubation with FITC-
Phalloidin (1:50, Invitrogen). Stained cultures were mounted on glass
slides and visualized using ﬂuorescence microscopy (Olympus BX61,
Jenoptik C14 camera).
Deafened guinea pigs
All procedures were performed in accordance with the ethical
guidelines of Karolinska Institutet, and were consistent with national
regulations for the care and use of animals (approval N 35/07). Four-
teen pigmented guinea pigs were tested for normal hearing using the
Preyer's reﬂex prior to surgery. All animals received an intracochlear
stimulus electrode and an osmotic pump as described previously
(Fransson et al., 2010; Maruyama et al., 2008). The stimulus device
consisted of a platinum–iridium electrode inserted into the cochlea,
and a ground electrode placed in the middle ear cavity. Both elec-
trodes were connected to a percutaneous connector cemented to
the skull. At Day 0, the osmotic pump cannula was loaded with oto-
toxic neomycin to provide intracochlear infusion for 48 h. This caused
a hearing loss of 40–60 dB. Animals were then divided in two groups
and treated (infusion rate 0.5 μl/h) for 2 weeks with recombinant
Cometin (1 μg/ml) or, as a negative control, artiﬁcial perilymph (AP)
mimicking the inner ear ﬂuid. At the end of treatment, the osmotic
pumps were removed but the animals were studied for two addition-
al weeks. The electrically-evoked brainstem responses (eABR) was
recorded to assess auditory function at days 2, 7, 14, 21 and 28 as pre-
viously described (Fransson et al., 2010; Hall, 1990). Brieﬂy, the ani-
mals were anaesthetized and placed in a sound proof box, and
eABRs recorded using a SigGen System2 signal analyzer (Tucker-Davies
Technologies). Responses were summed to alternate polarity mono-
phasic current pulses presented at 50 pps. Thresholds were deﬁned as
the lowest stimulus level that evoked a reproducible waveform. After
the last recording, animals were sacriﬁced by cardiac perfusion (37 °Csaline followed by cold 2.5% glutaraldehyde in 0.1 M phosphate buffer)
and the cochleas collected, dehydrated and embedded in Technovit
7100. For stereological analysis, 24-μm thick sections were prepared
and stained with hematoxylin and eosin. The optical fractionator
(Gundersen et al., 1988) was applied to estimate the total number of
spiral ganglion neurons in the Rosenthal's canal using the NEW CAST
(v2.14) software from Visiopharm.
Statistical analysis
Data were analyzed by one way Analysis of Variance (one way
ANOVA) followed by Multiple Comparisons versus Control Group,
Holm–Sidak method. P values are indicated in individual ﬁgures.
Results
Cometin is well conserved and forms a unique two-membered family
with Meteorin
In public databases, several mouse and human expressed se-
quence tags (ESTs) are similar to Meteorin and therefore automatical-
ly annotated as Meteorin-like. The name Meteorin originally refers to
the ability of the molecule to transform glial cells into cells with an
elongated tail, looking like meteors (Nishino et al., 2004). To indicate
the relationship to Meteorin but also to emphasize the difference be-
tween the molecules, we have renamed Meteorin-like to Cometin
(after a comet). Translated ESTs are approximately 40% identical to
Meteorin and the two molecules form a novel two-membered family
of conserved proteins with ten cysteine residues (Fig. 1). Mouse and
human Cometin are 77% identical 311 amino acid proteins with a pre-
dicted signal peptide and apparently no pro-sequence resulting in a
266 amino acid mature protein with a mass of 30 kDa. According to
the NCBI database, Cometin is located on mouse chromosome 11qE2
whereas the human version is found on chromosome 17q25.3. Analysis
of EST and genome sequences from other organisms suggests ortholo-
gues for Cometin in vertebrates including zebraﬁsh and the frog Xenopus
tropicalis, whereas no detectable orthologues are found in the inverte-
brates such as the nematode (Caenorhabditis elegans) or the fruit ﬂy
(Drosophila melanogaster) (Supplementary Material, S2).
Cometin is a classically secreted monomeric novel protein
To examine if Cometin is a secreted protein as predicted,we cloned a
C-terminally HIS-tagged version of mouse Cometin (mCMTN-HIS) into
a mammalian expression vector and transfected HEK293F cells. From
Fig. 2A it is evident that Cometin is effectively secreted and the mono-
mer has amolecularweight of approximately 34 kDawhich is including
the HIS tag. In cell lysates, Cometin is also found in themonomeric form
but some likely dimerization andmultimers are also evident. To be able
to study biochemical and eventually functional properties of Cometin,
recombinant protein was produced in HEK293F cells and puriﬁed by
metal afﬁnity chromatography. From SDS-PAGE analysis of the puriﬁed
protein in Fig. 2B, there is only one ~34 kDa band representing recom-
binant mCMTN-HIS and importantly no visible impurities. The puriﬁed
recombinant protein is recognized by a monoclonal antibody against
Cometin (Fig. 2C) and matrix-assisted laser desorption/ionization
time-of-ﬂight (MALDI-TOF) analysis suggests that the secreted protein
occurs as a monomer of 34 kDa (Fig. 2D). N-terminal sequence analysis
of mCMTN-HIS for 10 cycles of Edman degradation did not result in any
signals indicating that its N-terminus is blocked. SignalP prediction sug-
gests an N-terminal sequence of QYSSDL… for mature mCMTN (Fig. 1).
Cyclization of the N-terminal glutamine to a pyroglutamic acid would re-
sult in a negative result in Edman degradation. In order to conﬁrm the N-
terminal of puriﬁed mCMTN-HIS, it was subjected to “in gel” trypsin
cleavage followed by MALDI-TOF peptide mass ﬁngerprinting as well as
LC-ESI MS/MS peptide de novo sequencing. The analysis showed that
Fig. 1. Cometin is a novel secreted protein forming a family with Meteorin. Amino acid sequence alignment of Cometin (CMTN) and Meteorin (METRN) from mouse and human
(m/h). Predicted signal peptide is shown in bold and the cleavage site marked by an arrow (↓). Identical amino acids are shaded and cysteine residues in the mature sequence
are boxed. A potential N-glycosylation site in mouse Cometin is marked on a black background.
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with the sequence of the blocked N-terminal peptide (bQYSSDLCSWK,
1255.544 Da). The analyses also conﬁrmed most of the remaining
amino acid sequence of mCMTN-HIS. The calculated molecular mass of
mCMTN-HIS with the pyroglutamic acid at the N-terminus, the C-
terminal HIS-tag and ﬁve disulﬁde bridges is 31,128.2 Da. However,
MALDI-TOF MS resulted in two non-separated peaks with centers corre-
sponding to masses about 33,400 Da and 33,800 Da (Fig. 2D). No signals
could be detected at the calculated mass of the polypeptide chain alone,
suggesting that the protein is post-translationally modiﬁed. Since
mouseCometinhas onepotentialN-glycosylation site (Fig. 1), puriﬁed re-
combinant proteinwas incubatedwithN-Glycanasewhich decreased the
molecular weight to ~31 kDa indicating thatmCMTN-HIS is indeed a gly-
coprotein with N-linked oligosaccharides when expressed in HEK293F
cells (Fig. 2E). However, the N-glycosylation site in the mouse sequence
is not a conserved feature in other species and may therefore be without
functional importance (Supplementary Material, S2).
Cometin expression is highly restricted through nervous system
development
Initially, Cometin expression was analyzed using semi-quantitative
RT-PCR but we did not pick up any signiﬁcant expression in the moreFig. 2. Characterization of recombinant Cometin. A) Conditioned media and cell lysates fromm
tibody against mouse Cometin. The immunoreactive band corresponding to the mCMTN-HIS m
recombinantmCMTN-HIS. C) SDS-PAGE and immunostaining of serially dilutedpuriﬁed recomb
binant mCMTN-HIS showing a mass of 33.8 kDa with a shoulder at 33.4 kDa. E) N-Glycanase tthan 30 adult mouse tissues investigated. This is in agreement with
the GNF SymAtlas v1.2.4 (Su et al., 2004), where Cometin is not reliably
detected in any of the 60 mouse tissues examined by array. This indi-
cates that Cometin is not expressed in adults or, alternatively, restricted
to very small cell populations. To address expression at the cellular
level, mono- and polyclonal antibodies were generated in rat and
sheep respectively by recombinant Cometin immunization. The result-
ing antibodieswere screened by ELISA and immunohistochemistry test-
ed on rat brains manipulated to over express Cometin by unilateral
intrastriatal injection of lenti virus (Supplementary Material, S1). The
transduced striatal cells thus expressed Cometin at known coordinates
with the contralateral non-transduced side functioning as an internal
negative control. A few antibodies revealed identical cytoplasmic stain-
ing at the injection site while no signal was picked up in the contralat-
eral control side or after omission of primary antibody altogether
indicating that the antibodies are speciﬁc for Cometin. However, using
these antibodies, no signiﬁcant endogenous Cometin expression was
found in coronal sections throughout the adult mouse brain.
To address Cometin expression during development, ISH was done at
different embryonic stages (E9–E14.5). The earliest time point at which
Cometin could be detected was at E9.5 in ﬂoor plate cells throughout
the neural tube (Fig. 3A). Between E9.5 and E11.5 Cometin expression
is found predominantly in the ﬂoor plate cells, but from E13.5, Cometinock and mCMTN-HIS transfected HEK293F cells analyzed by western blotting with an an-
onomer is indicated with an arrow (→). B) SDS-PAGE and Coomassie staining of puriﬁed
inant Cometinwith an antibody againstmouse Cometin. D)MALDI-TOF analysis of recom-
reatment of recombinant mCMTN-HIS reduce the molecular weight to ~31 kDa.
Fig. 3. Cometin expression during development assessed by in situ hybridisation. A) Cometin is selectively expressed in the ﬂoor plate throughout the central nervous system from
E9.5. From E13.5 Cometin starts to be expressed in the inner ear. B) From E13.5 cometin expression could be detected in the DRGs. C) From E14.5, Cometin is expressed in cartilage
primordia, the olfactory epithelia and lungs. * develops into the inner ear. ** the cartilage primordium of the head of the left radius. SC: spinal cord; HB: hind brain; MB: midbrain;
DRG: dorsal root ganglia. Scalebar shown in E9.5 SC is 200 μm and applies to all images. See Supplementary Material (S3) for a direct comparison to Meteorin expression.
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pression at E14.5. Similarly, at E13.5, the DRGs begin to express Cometin
and a stronger signal was picked up one day later (Fig. 3B). Interestingly,
the DRGs located at the hindbrain level seem to have a slightly reduced
expression of Cometin compared to DRGs at the spinal cord level. From
E14.5, CometinmRNAwas found very strongly expressed in cartilage pri-
mordia throughout the embryo exempliﬁedby the frontal bone, branchial
arches and radius (Fig. 3C). At this developmental stage, the olfactory ep-
ithelium and epithelial layer lining the bronchioles also express some
Cometin mRNA. Throughout development, we did not note any differ-
ences in the expression pattern between male and female embryos. To-
gether our analysis demonstrates that Cometin expression is
developmentally regulated and found only in very few cell populationsprimarilywithin the nervous system.Adirect comparison toMeteorin ex-
pression fromE9 to E14.5 can be found in SupplementaryMaterial (S3). It
is clear that Meteorin is much more widely expressed during develop-
ment in agreement with previous expression analysis (Nishino et al.,
2004).
To investigate if the Cometin transcript is translated in vivo, we
analyzed protein expression at E14.5 through immunohistochemistry
(IHC). Generally, the protein expression pattern detected by IHC
matches well the mRNA expression pattern detected by ISH (Fig. 4).
An intense signal is seen in cartilage primordium, most likely from os-
teoblasts forming a cell layer over bone surfaces on which matrix is
being formed. Furthermore, the ﬂoor plate cells express Cometin protein
in agreement with the ISH analysis. Low mRNA levels were originally
Fig. 4. Cometin expression at E14.5 assessed by immunohistochemistry. A) Coronal section through the caudal level including the medulla oblongata and along the vertebrate to the
spinal cord. Note that Cometin expression is restricted to a few discrete locations. B) The mid-shaft region of the right humerus. C) Cometin expressing osteoblasts surrounding the
rib surfaces. D) Expression of Cometin in the ﬂoor plate. Abbreviations are cc: central canal, drg: dorsal root ganglia, fp: ﬂoor plate, lu: lung, mo: medulla oblongata, ob: osteoblasts,
sc: spinal cord and vb: vertebrate. Scale bar in B is 100 μm and applies to C and D as well.
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from the IHC analysis most likely because corresponding protein levels
in these tissues were below the detection limit of our antibodies.Cometin promotes neurite outgrowth from DRGs via the Jak-STAT3 and
MEK-ERK pathways
It has previously been demonstrated that Meteorin induce neurite
outgrowth fromDRGs as effectively as the classical neurotrophic factors
NGF, BDNF and NT3 (Nishino et al., 2004). Because the new family
member Cometin is likewise expressed in DRGs during development,
we tested both proteins on cultures of dissociated DRGs with Meteorin
also functioning as a positive control. Without trophic support, neurite
outgrowth from DRG cells is very limited whereas in the presence of
Cometin, long β-III-Tubulin positive neurites are formed (Figs. 5A and
C). The observed neurite outgrowth is dose dependent and not signiﬁ-
cantly different from that induced by Meteorin. Meteorin is known to
function through the Jak-STAT3 pathwaywith some additional involve-
ment of the MEK-ERK pathway (Lee et al., 2010). In agreement with
this, we observed signiﬁcant inhibition of Meteorin induced neurite
outgrowth in the presence of Jak inhibitor I (JAKiI) andmarked reduction
was also evident with the MEK inhibitor U0126 (Fig. 5B). For Cometin,
addition of either JAKiI or U0126 reduced neurite outgrowth to the neg-
ative control level. This indicates that both the Jak-STAT3 and MEK-ERK
pathways are involved in transducing the effect of Cometin. Interestingly,
simultaneous addition of Cometin and Meteorin had an additive effect
with signiﬁcantly more neurites compared to stimulation with each fac-
tor alone at saturating doses (Fig. 5D).Cometin increases SVZ neuroblast migration
Numerous cell lines and primary cultures were investigated in
search for biological effects of Cometin. The SVZ of the lateral ventri-
cle contains neural stem cells which give rise to migrating neuroblasts
(Alvarez-Buylla and Garcia-Verdugo, 2002). Addition of Cometin to rat
SVZ explants caused a signiﬁcant increase of cell migration and nearly
doubled the migratory distance compared to control (Figs. 6A–C). The
magnitude of this effectwas similar to that of stromal cell derived factor
1a (SDF1a), which is a known potent regulator of in vivo neuroblast mi-
gration from the SVZ following brain injury (Imitola et al., 2004; Robin
et al., 2006; Thored et al., 2006). Immunostaining of stimulated SVZ ex-
plant cultures with antibodies against DCX supported that the migrating
cells were indeed neuroblasts (Fig. 6D). The actin cytoskeleton plays a
central role in cell migration and SDF1a is known to induce actin poly-
merisation in multiple systems as an essential part of the migratory pro-
cess (Jones et al., 2006; Voermans et al., 2001). Using FITC conjugated
phalloidin, which speciﬁcally binds F-actin, we found that Cometin in-
duces actin polymerisation similar to SDF1a in the SVZ explants as fur-
ther evidence for an effect on migration (Figs. 6E–G). Taken together,
our data demonstrate that Cometin promotes neuroblast migration.
Cometin supports spiral ganglion neuron survival and electrical respon-
siveness in vivo
We observed developmentally regulated Cometin expression in
the inner ear starting at E13.5 (Fig. 3A). Expression of neurotrophic
factors are important during inner ear development and furthermore
for maintenance in the adult state (Pettingill et al., 2007). To further
Fig. 5. Cometin induces neurite outgrowth in DRG cultures through the Jak and MEK kinases. A) Quantiﬁcation of neurite outgrowth showing a similar dose–response relationship
for both Cometin and Meteorin. B) Neurite outgrowth induced by Cometin is inhibited by 1 μM JakiI or 1 μMMEK inhibitor (U0126) as is also the case for Meteorin. C) Example of
neurite outgrowth from Control, Cometin and Meteorin (300 ng/ml) treated cells. Scale bar: 100 μm. D) Additive effect of Cometin and Meteorin (300 ng/ml). The * indicates a sig-
niﬁcant difference from addition of either factor alone (Pb0.05).
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used a guinea pigmodel allowing both functional and structural studies
(Shinohara et al., 2002). In this model, the auditory sensory cells (hair
cells) are destroyed by local delivery of the ototoxic agent neomycin
to the inner ear. The loss of the sensory cells causes not only permanent
hearing loss, but is also accompanied by a secondary degeneration of
the auditory primary afferent neurons, the spiral ganglion cells. The
progressive degeneration of spiral ganglion neurons can be followed
by recording eABR,which give an indication of the electrical responsive-
ness of the auditory neurons. In the present experiment, a two-day in-
fusion of neomycin produced a signiﬁcant hearing loss of 40–60 dB.
The hearing impaired animals were subsequently divided into two
groups and treated by infusion of recombinant Cometin or a saline solu-
tion (artiﬁcial inner ear perilymph) as a negative control (Fig. 7A). As ap-
parent in Fig. 7B, both treatment groups started out at approximately the
same threshold level (~40 μA) but after 2 weeks there was a signiﬁcant
difference (pb0.001) between the Cometin treated group retaining nor-
mal function and the control group displaying progressive impairment.
The pumps were then removed in both groups (day 14). In the control
animals, the threshold continued to increase and at the end of the exper-
iment, the eABR threshold was approximately 200 μA. In contrast, the
Cometin treatment resulted in a threshold lower than 50 μA throughout
the experiment, signifying a positive effect of the treatment. Interesting-
ly, this effect was maintained for at least 2 weeks beyond the treatment
period. The protective properties of Cometin were further supported by
stereological analysis of the spiral ganglion neurons in Rosenthal's canal.
In the Cometin treated group there were signiﬁcantly (pb0.001) morespiral ganglion neurons as compared to the control group (Fig. 7C). Ap-
proximately 14,000 spiral ganglion neurons remained in the treated an-
imals compared to only 7000 in the control group. For comparison, the
total number of spiral ganglion neurons in a normal guinea pig is ap-
proximately 35,000 (Watanabe et al., 2010). The remaining neurons in
the Cometin treated group retained normal morphology as evident in
Fig. 7D while the few remaining neurons in the non-treated group
were irregular and clearly degenerated (Fig. 7E).
Discussion
In this study we show that Cometin is a novel, well-conserved se-
creted protein that together with Meteorin forms a unique family of
neurotrophic factors. This protein family appears restricted to verte-
brates, which is also the case for the glial cell line-derived neurotrophic
factor (GDNF) family ligands and receptors (Airaksinen et al., 2006) and
the neutrophins and their receptors (Lanave et al., 2007). It has beenhy-
pothesized that these important families were formed as a result of
gene duplication at the origin of the vertebrates as they are required
to develop and support a more complex nervous system, which may
also be the case for Cometin and Meteorin.
We were unable to detect Cometin in the adult brain using various
techniques which is in agreement with public array data (Su et al.,
2004; Walker et al., 2004) as well as the Allen Brain Atlas (Lein et
al., 2007) and the BGEM in situ database (Magdaleno et al., 2006). To-
gether this suggests Cometin is not expressed in the adult brain. Al-
ternatively, very weak expression or very restricted expression in a
Fig. 6. Cometin stimulates migration of SVZ-derived neuroblasts. A) Quantiﬁcation of Cometin induced cell migration relative to non-stimulated control (Mean±SEM). SDF1a was
included as a positive control. Note that Cometin signiﬁcantly increase migration (* Pb0.001). B–C) Light microscopic examples of neuroblast migration increased by Cometin.
D) Migrating cells are DCX-positive. E–G) Actin polymerization, visualized by FITC-Phalloidin staining, is induced by Cometin and SDF1a. Scale bars are 50 μm on all images.
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deed found during development both at the mRNA and the protein
level indicating speciﬁc rather than general functions of the molecule.
Onset of Cometin expression in the inner ear at E13.5 (Fig. 3A) coin-
cides with the appearance of sensory hairs (Ruben, 1967). In medaka
ﬁsh, the homologous sequence is regulated by PAX transcription fac-
tors known to be involved in inner ear development (Ramialison et
al., 2008). With the hypothesis that neurotrophic factors expressed
in speciﬁc regions of the nervous system during development may
confer neuroprotection and restoration when reapplied to the same re-
gions during disease in adults, we examined the effect of exogenous de-
livery of Cometin in adult deafened guinea pigs. Indeed, using both
functional and stereological measures, we demonstrate effective Come-
tin mediated protection of spiral ganglion neurons (Fig. 7). Noticeably,
the protective effect was maintained for at least two weeks after treat-
ment cessation, suggesting that the treatment either supported neuro-
nal survival during a critical period or changed the local milieu so that
the spiral ganglion neurons could survive despite the loss of trophic
support from sensory cells. The effects of Cometin is comparable in
magnitude to what has previously been demonstrated using GDNF in
the same animal model (Fransson et al., 2010; Maruyama et al., 2008).
Deafness is a common disability, which in many cases occurs as a result
of loss of sensory hair cell followed by ongoing degeneration of the spi-
ral ganglion neurons similar to the in vivomodel used in this study. The
functional integrity of the spiral ganglion neurons are important to pre-
serve as the ganglia is target for cochlear implants which circumvents
the hair cells and directly stimulate the neurons electrically (Pettingill
et al., 2007).
Cometin appears in the DRGs at E13.5 and more intensely at E14.5
(Fig. 3B). During DRG development, the neurons are typically formed
around E11.5 whereas the satellite glia cells appear approximately
two days later (Lawson and Biscoe, 1979; Sims and Vaughn, 1979).
Hence, it is likely that Cometin is expressed by satellite glia surround-
ing and supporting the neurons in the ganglia. With this assumption
and because Meteorin is known to act on DRGs through glia (Jorgensen
et al., 2009; Nishino et al., 2004) we used this particular tissue forexplant cultures to functionally characterize the two-membered family.
We found that Cometin induces neurite outgrowth to the same extent
as Meteorin over a wide range of doses but interestingly an additive
effect was observed when both factors were added together (Fig. 5).
NT3 also works co-operatively with Meteorin in contrast to NGF,
BDNF and ciliary neurotrophic factor (CNTF) (Lee et al., 2010; Nishino
et al., 2004). Though little is known about the mechanism of action,
Meteorin is supposed to have a unique yet unidentiﬁed speciﬁc receptor
through which gp130 is recruited to activate the Jak-STAT3 pathway
with a possible downstream involvement of the MEK-ERK pathway
(Lee et al., 2010). In agreementwith this, we observedmore efﬁcient in-
hibition ofMeteorin-induced neurite outgrowth fromDRGswith Jak in-
hibitor I (JAKiI) compared to theMEK inhibitor U0126. For Cometin, we
observed complete arrest of neurite outgrowth with both inhibitors in-
dicating that both the Jak-STAT3 and MEK-ERK pathways are involved
in the signal transduction. This makes gp130 a likely interaction partner
for Cometin but an additional speciﬁc receptor is probably required for
signaling. Because of the additive effect of Cometin and Meteorin, each
ligandwould be expected to have a preferred receptor with little cross-
reaction. Identiﬁcation of the speciﬁc receptors for Cometin and
Meteorin is the next important step in elucidating themechanism of ac-
tion employed by this novel protein family.
Cometin mRNA is also found in the ﬂoor plate throughout the de-
veloping neural tube. This specialized cell population is located on the
ventral midline of the neural tube and spans the anteroposterior axis.
The ﬂoor plate is a well known inductive center that serves as an orga-
nizer of ventral cell fate aswell as to guide neuronal positioning and dif-
ferentiation along the dorsoventral axis (Placzek and Briscoe, 2005).
The secreted proteins Sonic Hedgehog Homolog and Netrin 1 are key
regulators of these respective events. Cometin, being a secreted protein
with a similar expression pattern, may well play a role in the differenti-
ation and survival of ventral cell populations generated during embry-
onic neurogenesis. Throughout the nervous system, newly formed
neurons normally migrate away from the proliferative zone towards
their ﬁnal destination. This movement requires signals to start, guide
and stop migration as well as changes in the cytoskeleton to mediate
Fig. 7. Cometin protects spiral ganglion neurons in vivo. A) Experimental outline. Brieﬂy, at t=0, all animals received an intracochlear stimulus electrode connected to an infusion pump. The
ototoxic drug Neomycinwas infused for two days to deafen the animals. The animals were then divided in two groups receiving Cometin or artiﬁcial perilymph (AP) for 12 days after which
thepumpswere removed. After another twoweeks, the animalswere sacriﬁced (†) and the tissue processed for stereological analysis of the inner ear. Electrically-evoked brainstem response
(eABR) thresholds were recorded at days 2, 7, 14, 21 and 28. B) Recorded eABR thresholds (Mean±SEM) throughout the experiment. Note that animals treated with Cometin retained very
low eABR thresholds in contrast to AP treated animals. C) Stereological analysis of the total number of spiral ganglion neurons at the end of the experiments (day 28). D and E show the spiral
ganglion from animals treated with Cometin and AP respectively. Neurons are indicated by arrowheads in D. *** signiﬁes pb0.001.
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strate that Cometin effectively stimulates migration concomitant with
actin polymerisation. Several other neurotrophic/growth factors, e.g.
GDNF, BDNF, insulin-like growth factor and vascular endothelial growth
factor have previously been reported to be involved in neuroblast migra-
tion from the SVZ along the rostralmigratory stream towards the olfacto-
ry bulb (Sun et al., 2010). Importantly, we ﬁnd here that the stimulatory
action onneuroblastmigrationbyCometin is comparable to that of SDF1a
which is a major regulator of neuroblast migration from the SVZ to the
damaged area after stroke (Robin et al., 2006).Conclusion
This study describes the discovery of Cometin from sequence to bio-
logical function in vivo. In summary, Cometin is a well-conserved secret-
ed neurotrophic protein with highly restricted and developmentally
regulated expression. It is involved in fundamental processes such as
neuroblast migration and neurite outgrowth most likely mediatedthrough the JAK-STAT3 and MEK-ERK pathways. Furthermore, Cometin
effectively protects spiral ganglion neurons in vivo and the beneﬁcial
effect is maintained after treatment cessation. Also importantly,
through these studies, the molecular tools have been created for future
investigation of Cometin.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.expneurol.2011.09.027.
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